USO 15014

GO29437: A phase ill, open-label, multicenter, randomized study evaluating the efficacy and safety of mpdl3280a (anti-pd-l1 antibody) in combination with carboplatin + paclitaxel or mpdl3280a in combination with carboplatin +nab-paclitaxel versus carboplatin + nab-paclitaxel in chemotherapy naive patients with stage iv squamous non-small cell lung cancer

Disease Types

Lung Cancer

Available at

BethesdaClintonColumbiaRockvilleSilver SpringWheaton


Cheryl A. Young, RN, BSN
(410) 964-2212 ext 1137